Background: Current NCCN guidelines recommend baseline and q 3 mo BCR-ABL fusion transcript levels in imatinib (IM)-treated chronic myelogenous leukemia (CML) responding to treatment (tx) to monitor ...

Although JAK2 inhibitors were proposed to be beneficial in chronic myeloid leukemia, myeloid transformation and STAT5 activation in BCR-ABL–positive leukemias are JAK2 independent. Mechanistic ...

BCR-ABL transcript levels be measured every 3 months. Bone-marrow cytogenetics be performed at 6 and 12 months from initiation of therapy. Bone-marrow cytogenetics be conducted again at 18 months ...

Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common mechanism of resistance is the ...

It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients.

Kenneth R. LaMontagne, Greg Hannon, Nicholas K. Tonks, Protein Tyrosine Phosphatase PTP1B Suppresses p210 bcr-abl-Induced Transformation of Rat-1 Fibroblasts and Promotes Differentiation of K562 Cells ...

The Acrometrix BCR-ABL external control panel is launched to quantitate BCR-ABL RNA accurately. The first of its kind, the product is useful to make a critical, timely, patient treatment decisions.

Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation Ruriko Tanaka; Shinya Kimura Disclosures Expert Rev Anticancer Ther. 2008;8 (9):1387-1398. 0 ...